Brevan Howard Capital Management’s Assembly Biosciences ASMB Stock Holding History

Brevan Howard Capital Management’s Portfolio ASMB Stock Details ASMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$308K	Buy	+11,112	New	+$317K	﹤0.01%	1597

Other funds holding ASMB

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Brevan Howard Capital Management's ASMB Position: Q1 2026 in Review

Brevan Howard Capital Management opened a new position in Assembly Biosciences (ASMB) in Q1 2026: 11,112 shares worth $308K. The stake represents ﹤0.01% of the portfolio and ranks #1597 among its holdings.

75 funds tracked by Wall St. Rank hold ASMB as of Q1 2026.

Brevan Howard Capital Management held 11,112 shares of Assembly Biosciences worth $308K as of Q1 2026.
Assembly Biosciences was a new Brevan Howard Capital Management position in Q1 2026.
Assembly Biosciences made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1597 holding.
75 funds tracked by Wall St. Rank held Assembly Biosciences as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.